COVID-19 and smoking

Print on Demand. Lieferbar innerhalb von 7 bis 10 Tagen

There is currently insufficient information to confirm any link between nicotine in the prevention or treatment of COVID-19. WHO urges researchers, scientists and the media to be cautious about amplifying unproven claims that tobacco or nicotine could reduce the risk of COVID-19. WHO is constantly evaluating new research, including that which examines the link between tobacco use, nicotine use, and COVID-19. The harms of tobacco use are well-established. Tobacco causes 8 million deaths every year from cardiovascular diseases, lung disorders, cancers, diabetes, and hypertension. Smoking tobacco is also a known risk factor for severe disease and death from many respiratory infections. In the COVID-19 pandemic, questions have been asked about clinical outcomes for smokers, and whether they are equally susceptible to infection, and if nicotine has any biological effect on the SAR-CoV-2 virus (the virus that causes COVID-19). At the time of writing, one clinical trial to test the effects of nicotine has been announced, but no trial registration record was found as of 12 May 2020.

Mohamed Abdel-Raheem Ali Abdel-Raheem, Pests & Plant Protection Department, Agricultural and Biological Research Institute, National Research Centre, Le Caire, Égypte, et Dr. Lamiaa Fingan Nashi Al-Maliki, Department of Molecular and Medical biotechnology, College of Biotechnology, Al-Nahrain University, Bagdad, Iraq.